Street actors in Minnie Mouse costumes pass by in front of the AMC movie theater at night in the Times Square area of New York, October 15, 2020.
Amir Hamja | Bloomberg | Getty Images
Take a look at the companies that are making headlines in mid-day trading.
AMC Entertainment – Shares of the cinema chain fell by more than 4% in debt after the company said it could sell up to 50 million of its Class A stock as part of a “shelf offer.”
Levi Strauss – The denim retailer gained more than 1% after Guggenheim raised its price target on the company to $ 24, up from an advance target of $ 20. The new forecast is 21% above where the stock closed Tuesday. “We are encouraged by the company’s offensive strategy, strong brand, experienced management team, and healthy financial position… which we believe will enable LEVI to emerge from the COVID-19 crisis in stronger competitive position, “the company said in a note to clients.
Tesla – Shares of the electric vehicle company rose more than 1% as the stock continues to bounce back from recent sales pressures. Last week the stock fell 4.8% after the company was added to the S&P 500. So far this week, Tesla has gained about 2.4%.
2U Inc – Education software company’s stock price jumped more than 6% after Needham announced it as a top choice for 2021. Wall Street company said 2U has been a supporter of delays from the move to education on -line. The stock has gained 76% this year.
Dynatrace – Shares gained more than 3% after BTIG began broadcasting on the software company with a buy rate. BTIG said it sees growth in the application performance management market in 2021 as more companies invest in digital transformation. The company’s $ 56 price target suggests a 30% rally in the next 12 months.
AstraZeneca – The pharmaceutical stock gained around 1% after the UK approved the Covid-19 vaccine developed by AstraZeneca and Oxford University.
Emergency BioSolutions – Shares of the life sciences company rose 2.7% after Emergent and Mount Sinai Health Systems embarked on a new clinical program looking at potential immune treatment for Covid-19. The research program is funded by the Department of Defense.
– CNBC’s Pippa Stevens, Fred Imbert and Jesse Pound made a statement.
Subscribe to CNBC PRO for unique insights and analysis, and live business day programs from around the world.